NCT06299371View on ClinicalTrials.gov

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2029

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Adebrelimab

Adebrelimab IV

DRUG

paclitaxel for injection (albumin bound)

paclitaxel for injection (albumin bound) IV

DRUG

Cisplatin or Carboplatin

Cisplatin or Carboplatin IV

All Listed Sponsors
lead

Liaoning Cancer Hospital & Institute

OTHER

NCT06299371 - Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | Biotech Hunter | Biotech Hunter